<?xml version='1.0' encoding='utf-8'?>
<document id="26668209"><sentence text="Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters."><entity charOffset="14-26" id="DDI-PubMed.26668209.s1.e0" text="Ketoconazole" /><entity charOffset="136-148" id="DDI-PubMed.26668209.s1.e1" text="Ketoconazole" /><entity charOffset="150-159" id="DDI-PubMed.26668209.s1.e2" text="Ritonavir" /><entity charOffset="161-175" id="DDI-PubMed.26668209.s1.e3" text="Clarithromycin" /><entity charOffset="181-193" id="DDI-PubMed.26668209.s1.e4" text="Itraconazole" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e0" e2="DDI-PubMed.26668209.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e0" e2="DDI-PubMed.26668209.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e0" e2="DDI-PubMed.26668209.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e0" e2="DDI-PubMed.26668209.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e0" e2="DDI-PubMed.26668209.s1.e4" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e1" e2="DDI-PubMed.26668209.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e1" e2="DDI-PubMed.26668209.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e1" e2="DDI-PubMed.26668209.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e1" e2="DDI-PubMed.26668209.s1.e4" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e2" e2="DDI-PubMed.26668209.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e2" e2="DDI-PubMed.26668209.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e2" e2="DDI-PubMed.26668209.s1.e4" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e3" e2="DDI-PubMed.26668209.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26668209.s1.e3" e2="DDI-PubMed.26668209.s1.e4" /></sentence><sentence text="Ketoconazole is a potent CYP3A4/5 inhibitor and, until recently, recommended by the Food and Drug Administration (FDA) and the European Medicines Agency as a strong CYP3A4/5 inhibitor in clinical drug-drug interaction (DDI) studies"><entity charOffset="0-12" id="DDI-PubMed.26668209.s2.e0" text="Ketoconazole" /></sentence><sentence text=" Ketoconazole sporadically causes liver injury or adrenal insufficiency"><entity charOffset="1-13" id="DDI-PubMed.26668209.s3.e0" text="Ketoconazole" /></sentence><sentence text=" Because of this, the FDA and European Medicines Agency recommended suspension of ketoconazole use in DDI studies in 2013"><entity charOffset="82-94" id="DDI-PubMed.26668209.s4.e0" text="ketoconazole" /></sentence><sentence text=" The FDA specifically recommended use of clarithromycin or itraconazole as alternative strong CYP3A4/5 inhibitors in clinical DDI studies, but many investigators have also used ritonavir as an alternative"><entity charOffset="41-55" id="DDI-PubMed.26668209.s5.e0" text="clarithromycin" /><entity charOffset="59-71" id="DDI-PubMed.26668209.s5.e1" text="itraconazole" /><entity charOffset="177-186" id="DDI-PubMed.26668209.s5.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.26668209.s5.e0" e2="DDI-PubMed.26668209.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26668209.s5.e0" e2="DDI-PubMed.26668209.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26668209.s5.e0" e2="DDI-PubMed.26668209.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26668209.s5.e1" e2="DDI-PubMed.26668209.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26668209.s5.e1" e2="DDI-PubMed.26668209.s5.e2" /></sentence><sentence text=" Although the effects of these clinical CYP3A4/5 inhibitors on other CYPs are largely established, reports on the effects on the broad range of drug transporter activities are sparse" /><sentence text=" In this study, the inhibitory effects of ketoconazole, clarithromycin, ritonavir, and itraconazole (and its CYP3A4-inhibitory metabolites, hydroxy-, keto-, and N-desalkyl itraconazole) toward 13 drug transporters (OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, MATE2-K, P-gp, BCRP, MRP2, MRP3, and BSEP) were systematically assessed in transporter-expressing HEK-293 cell lines or membrane vesicles"><entity charOffset="42-54" id="DDI-PubMed.26668209.s7.e0" text="ketoconazole" /><entity charOffset="56-70" id="DDI-PubMed.26668209.s7.e1" text="clarithromycin" /><entity charOffset="72-81" id="DDI-PubMed.26668209.s7.e2" text="ritonavir" /><entity charOffset="87-99" id="DDI-PubMed.26668209.s7.e3" text="itraconazole" /><entity charOffset="140-148" id="DDI-PubMed.26668209.s7.e4" text="hydroxy-" /><entity charOffset="150-155" id="DDI-PubMed.26668209.s7.e5" text="keto-" /><entity charOffset="161-184" id="DDI-PubMed.26668209.s7.e6" text="N-desalkyl itraconazole" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e0" e2="DDI-PubMed.26668209.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e0" e2="DDI-PubMed.26668209.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e0" e2="DDI-PubMed.26668209.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e0" e2="DDI-PubMed.26668209.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e0" e2="DDI-PubMed.26668209.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e0" e2="DDI-PubMed.26668209.s7.e5" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e0" e2="DDI-PubMed.26668209.s7.e6" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e1" e2="DDI-PubMed.26668209.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e1" e2="DDI-PubMed.26668209.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e1" e2="DDI-PubMed.26668209.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e1" e2="DDI-PubMed.26668209.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e1" e2="DDI-PubMed.26668209.s7.e5" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e1" e2="DDI-PubMed.26668209.s7.e6" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e2" e2="DDI-PubMed.26668209.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e2" e2="DDI-PubMed.26668209.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e2" e2="DDI-PubMed.26668209.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e2" e2="DDI-PubMed.26668209.s7.e5" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e2" e2="DDI-PubMed.26668209.s7.e6" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e3" e2="DDI-PubMed.26668209.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e3" e2="DDI-PubMed.26668209.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e3" e2="DDI-PubMed.26668209.s7.e5" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e3" e2="DDI-PubMed.26668209.s7.e6" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e4" e2="DDI-PubMed.26668209.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e4" e2="DDI-PubMed.26668209.s7.e5" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e4" e2="DDI-PubMed.26668209.s7.e6" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e5" e2="DDI-PubMed.26668209.s7.e5" /><pair ddi="false" e1="DDI-PubMed.26668209.s7.e5" e2="DDI-PubMed.26668209.s7.e6" /></sentence><sentence text=" In vitro findings were translated into clinical context with the basic static model approaches outlined by the FDA in its 2012 draft guidance on DDIs" /><sentence text=" The results indicate that, like ketoconazole, the alternative clinical CYP3A4/5 inhibitors ritonavir, clarithromycin, and itraconazole each have unique transporter inhibition profiles"><entity charOffset="33-45" id="DDI-PubMed.26668209.s9.e0" text="ketoconazole" /><entity charOffset="92-101" id="DDI-PubMed.26668209.s9.e1" text="ritonavir" /><entity charOffset="103-117" id="DDI-PubMed.26668209.s9.e2" text="clarithromycin" /><entity charOffset="123-135" id="DDI-PubMed.26668209.s9.e3" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.26668209.s9.e0" e2="DDI-PubMed.26668209.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26668209.s9.e0" e2="DDI-PubMed.26668209.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26668209.s9.e0" e2="DDI-PubMed.26668209.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26668209.s9.e0" e2="DDI-PubMed.26668209.s9.e3" /><pair ddi="false" e1="DDI-PubMed.26668209.s9.e1" e2="DDI-PubMed.26668209.s9.e1" /><pair ddi="false" e1="DDI-PubMed.26668209.s9.e1" e2="DDI-PubMed.26668209.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26668209.s9.e1" e2="DDI-PubMed.26668209.s9.e3" /><pair ddi="false" e1="DDI-PubMed.26668209.s9.e2" e2="DDI-PubMed.26668209.s9.e2" /><pair ddi="false" e1="DDI-PubMed.26668209.s9.e2" e2="DDI-PubMed.26668209.s9.e3" /></sentence><sentence text=" None of the alternatives to ketoconazole provided a clean inhibition profile toward the 13 drug transporters evaluated"><entity charOffset="29-41" id="DDI-PubMed.26668209.s10.e0" text="ketoconazole" /></sentence><sentence text=" The results provide guidance for the selection of clinical CYP3A4/5 inhibitors when transporters are potentially involved in a victim drug's pharmacokinetics" /><sentence text=" " /></document>